Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PREDICTORS OF RESPONSE TO 2ND-LINE ENDOCRINE THERAPY FOR BREAST-CANCER
Autore:
CHEUNG KL; WILLSHER PC; PINDER SE; ELLIS IO; ELSTON CW; NICHOLSON RI; BLAMEY RW; ROBERTSON JFR;
Indirizzi:
CITY HOSP NOTTINGHAM,PROFESSORIAL SURG UNIT,HUCKNALL RD NOTTINGHAM NG5 1PB ENGLAND CITY HOSP NOTTINGHAM,PROFESSORIAL SURG UNIT NOTTINGHAM NG5 1PB ENGLAND UNIV WALES COLL CARDIFF,TENOVUS INST CANC RES CARDIFF CF4 4XX S GLAM WALES
Titolo Testata:
Breast cancer research and treatment
fascicolo: 3, volume: 45, anno: 1997,
pagine: 219 - 224
SICI:
0167-6806(1997)45:3<219:PORT2E>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESTROGEN-RECEPTOR; IMMUNOCYTOCHEMICAL LOCALIZATION; EXPRESSION; SENSITIVITY; TISSUE;
Keywords:
BREAST CANCER; RESPONSE; SECOND-LINE ENDOCRINE THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
K.L. Cheung et al., "PREDICTORS OF RESPONSE TO 2ND-LINE ENDOCRINE THERAPY FOR BREAST-CANCER", Breast cancer research and treatment, 45(3), 1997, pp. 219-224

Abstract

This study reports on factors predicting response to second-line endocrine therapy in 250 patients with breast cancer for which they were assessable for response by the International Union Against Cancer (UICC) criteria. Clinical details relating to first-line endocrine therapy were available for all patients. We have not included in this study patients who received first-line endocrine therapy but did not or have not yet proceeded to second-line hormone therapy - e.g. died from rapidly progressive disease, started chemotherapy for rapidly progressive disease, or remained in long-term remission on first-line endocrine therapy. One hundred and fifty nine patients (72%) achieved remission (objective response and static disease [OR + SD]) on first-line endocrinetherapy with a median duration of 19 months. For second-line endocrine therapy the remission rate was 53% (132/225) with a median duration of 15 months. Tumour grade and oestrogen receptor status of the primary tumour were shown to be independent predictors of response to second-line endocrine therapy while response to first-line endocrine therapywas a predictor of the duration of response to second-line endocrine therapy. In the sub-group of patients who showed OR or SD to both first and second-line therapies, there was no correlation between the timeto progression (TTP) on first and second-line therapies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 00:33:48